Semaglutide on the NHS in Scotland: access, eligibility and what to do next

What the official guidance says about semaglutide for weight loss in Scotland

The Scottish Medicines Consortium accepted semaglutide (Wegovy) for use within NHS Scotland for weight management in adults, subject to conditions broadly aligned with the licensed indication: a BMI of 30 or above, or 27 or above where a weight-related condition such as hypertension, dyslipidaemia or type 2 diabetes is present. NHS Inform Scotland summarises the relevant medicines and conditions clearly and is worth a quick check if you want the official patient-facing version.

In practice, SMC acceptance is only the first gate. Scottish Health Boards then decide whether to commission services and at what pace. Some Boards have established tier-3 weight management pathways; others are still developing capacity. The result is that two people in Scotland with identical clinical profiles may have entirely different experiences depending on their postcode. That is not a criticism of the system (it reflects the scale of the task) but it is the honest answer to why many people find NHS access difficult to navigate.

Unlike the position in England, where NHS England's phased rollout (tied to NICE TA1026 for tirzepatide and TA875 for semaglutide) follows a nationally published timetable, Scotland has no equivalent public schedule. If you want a fuller picture of whether Wegovy is available on the NHS in Scotland, including what the SMC conditions mean in practice, that is covered in detail separately. If your GP surgery is unsure whether a local pathway exists, that uncertainty is real.

The gap between guidance and what GPs can actually prescribe in Scotland

Even where an SMC acceptance exists, GPs in Scotland cannot simply write a Wegovy prescription off their own bat within the NHS. Access is conditional on referral to, or involvement of, a specialist weight management service, the same multidisciplinary structure that NICE TA875 requires in England. Those services have long waiting lists in most areas.

Semaglutide is also licensed for a maximum of two years under NICE's recommendation, and the same spirit applies in SMC guidance: it is not a lifelong NHS prescription in the way a statin might be. Progress is reviewed, and continuation depends on achieving meaningful weight loss, typically defined as at least 5% of starting body weight after six months on the maintenance dose.

One practical step worth taking before anything else: call your GP surgery and ask whether your Health Board has a commissioned weight management service accepting referrals. That single call takes under a minute and gives you real local information rather than speculation. If the answer is a waiting list of twelve months or more, understanding how Wegovy fits into NHS Scotland and what alternatives exist may help you decide on your next step.

If you want to compare what the NHS England rollout looks like for context, the picture for semaglutide access in England is covered separately.

Ozempic, Wegovy and the distinction that matters in Scotland

A persistent source of confusion in Scotland, as elsewhere in the UK, is the relationship between Ozempic and Wegovy. Both contain semaglutide. Ozempic is licensed for type 2 diabetes management; Wegovy is licensed for weight management. They are not interchangeable on the NHS, and prescribing Ozempic off-label for weight loss is not standard NHS practice in Scotland. The MHRA is clear that GLP-1 medicines should be used within their licensed indications.

The 2.4 mg weekly dose used for weight management in Wegovy is higher than the diabetes doses available in Ozempic; the two products have different titration schedules and different licensed populations. Anyone who has been offered Ozempic for weight loss through an unofficial channel should be cautious: that is not a licensed or supervised arrangement. You can read more about how Wegovy works as the licensed weight-management option if that distinction is useful.

The MHRA also approved a higher 7.2 mg semaglutide dose (Wegovy) in January 2026, with a dedicated single-dose pen approved in April 2026, though NHS access to that dose tier in Scotland will depend on further commissioning decisions and is not yet routine.

Private semaglutide in Scotland: what a legitimate route looks like

For people in Scotland who do not meet NHS criteria, face long waits, or simply prefer to start sooner, a private prescription through a GPhC-registered online pharmacy is a legal and regulated option. The key word is regulated: the pharmacy must appear on the GPhC register, and every prescription must follow a clinical assessment by a qualified prescriber.

At nume, that assessment is personally reviewed by a GPhC-registered Independent Prescriber on the same day you submit your consultation. There are no subscriptions and no automatic renewals; each repeat order is clinically re-reviewed. The full process (consultation, prescription, treatment and free next-working-day delivery) is covered at one transparent price, with aftercare available seven days a week. If you are based in Scotland and want to understand whether you are likely to be suitable, the Scotland-specific buying guide for Wegovy covers the practical detail, and our broader weight-loss treatment overview sets out the full picture. For those who have already done their research and want to proceed, you can also buy Wegovy direct through our regulated service without needing a separate GP referral.

One sensible check before placing any order with any online pharmacy: look up the pharmacy's name on the GPhC register. It takes thirty seconds and immediately tells you whether you are dealing with a registered premises. Unregistered sellers offering these medicines without a clinical assessment are the source of the counterfeit pen problem the MHRA has been tackling since 2023. The risk is real.

If you are ready to see whether treatment is right for you, check your eligibility with a free consultation.